Personal email: desnoyer@gmail.com GENERAL MANAGEMENT: Results-focused, strategic global business leader providing entrepreneurial spirit and intrapreneurial expertise to drive innovation programs and emerging business opportunities for high revenue and margin growth. Proven record of leading cross-functional teams to deliver advanced products that access and develop new markets in the biotechnology and medical device (drug-device combination product) industries. PROFICIENCIES: Global Strategic Planning • Emerging Businesses • Organization Building • Innovation P&L Management • Business Development • Alliance Management • Global Marketing Product Launch • Product Development

Head of Strategic Innovation, BD Medical - Medication & Procedural Solutions @ CORPORATE PROFILE: Becton Dickinson is a leading med tech company with ~$29.3B market cap and >45,000 FTEs; focused on delivering innovative solutions to improve medication management & drug delivery, promote infection prevention, enhance the diagnosis of infectious diseases & cancers, support diabetes management, and advance cellular research. POSITION PROFILE: Responsible for driving innovation and growth for the Medication & Procedural Solutions Division, BD’s largest division, through development and execution of white space, adjacency, and pan-platform strategies. ACHIEVEMENTS: BUSINESS GROWTH STRATEGY / INNOVATION • Tasked to build on BD’s legacy of innovation and ensure divisional growth is not dependent on silos of existing business platforms. • Building Innovation System that spans core platforms but also considers new business opportunities. • Managing the Innovation Council, the governing body for the Innovation System led by the Division President. Facilitating opportunity generation and decision-making by advancing a steady cadence of new proposals alongside a fail fast mentality. • Embedding innovation mindset across Division by actively promoting innovation frameworks and cultural elements. Creating processes to uphold rigor of strategic plans and integrate Innovation System with key principles of the Product Development System to provide a comprehensive portfolio management approach that accelerates progression of innovation initiatives. • Crafting Division’s first disease state-specific strategy to transform BD from a general purpose, ancillary player to a major partner in care for a high burden disease area. From 2014 to Present (1 year) Senior Director & Head of Advanced Healing Technologies Franchise @ CORPORATE PROFILE: At $15B market cap with $4.6B annual revenue and ~14,000 FTEs, S&N is a leading provider of advanced surgery products for orthopedic reconstruction, trauma, sports medicine, and advanced wound care. POSITION PROFILE: Hired to create new growth franchise with a portfolio of biologics and biomaterials products tailored to improve healing. Responsible for business strategy, product development, and marketing with global P&L of ~$70M revenue. ACHIEVEMENTS: PRODUCT DEVELOPMENT & COMMERCIAL EXECUTION • Led cross-functional team to institute appropriate design and development controls and clarify clinical and regulatory strategy for S&N's first drug-device combination product. Pilot clinical study initiated within 18 months. • Delivered next generation platform technology to compete in biocomposite sector of sports medicine fixation device market, the largest and fastest growing segment. Launched differentiated HEALICOIL◊ REGENESORB Suture Anchor in Q4 2013; exceeded 2014 revenue target by ~33%. Received 510(k) clearance for second platform product in Q1 2015. • Established advisory board of KOLs in sports medicine and orthopedics to help steer product development, market access, and commercialization activities. • This ultimately drove ~$70M in revenue in 2014, over-achieving target by ~12% and delivering ~20% growth versus prior year. • Increased investment per annum through execution of strategic plan. BUSINESS DEVELOPMENT / LICENSING & DISTRIBUTION • Directed and prioritized business development initiatives for Franchise, including researching and identifying opportunities, modeling financials, and presenting to Division President. • Won approval to enter into Licensing & Distribution agreements in quick win bone graft substitute and platelet-rich plasma areas. Managed external alliances. Progressed several advanced biologic and biomaterial technologies to late stage diligence. From 2012 to 2014 (2 years) Greater Boston AreaDirector & Head of Advanced Healing Technologies Franchise @ POSITION PROFILE: Hired to create new growth franchise with a portfolio of biologics and biomaterials products tailored to improve healing. Responsible for business strategy, product development, and marketing with global P&L of ~$70M revenue. ACHIEVEMENTS: NEW GROWTH FRANCHISE CREATION • Formulated comprehensive business plan and secured investment from C-level management to create new growth franchise based on biologics and biomaterials to improve outcomes in endoscopic soft tissue repair and orthopedic surgery. • Within 90 days, recruited specialists in science, engineering, and marketing to build strong, cohesive team with necessary competencies to realize growth potential of new business. • Developed 5-year strategic plan comprising balanced portfolio of organic and inorganic programs to enable Smith & Nephew’s entry into biologics and biomaterials market and to optimize execution with lowest risk profile. • This established the Advanced Healing Technologies Franchise, which, with planned incremental peak revenue of $900M, is positioned to provide aggressive growth for current $3.3B Advanced Surgical Devices Division. • Owing to these achievements, was selected by senior management to participate as one of four divisional employees in the inaugural class of the CEO Leadership Forum for development of future executives of the company. From 2011 to 2012 (1 year) Greater Boston AreaManager, Strategic Planning @ COMPANY PROFILE: Abbott Vascular, a division of Abbott Laboratories, is the leading developer (~$2.5B annual revenue, ~2,000 FTEs) of interventional products for cardiovascular and peripheral vascular disease. POSITION PROFILE: Reporting to the VP, Strategic Marketing and responsible for enabling and driving new business growth, with emphasis on inorganic growth, in accordance with Abbott Vascular's long-range plan. Acted as liaison between Division and Abbott Ventures / Corporate Business Development. ACHIEVEMENTS: BUSINESS EXPANSION / MERGERS & ACQUISITIONS • Facing intense competitive pressure in the drug-eluting stent market, Abbott Vascular wanted to diversify its portfolio by entering the percutaneous Structural Heart space, believed to be the next major growth driver for interventional cardiology. • Partnered with Abbott Ventures and Corporate Business Development to build an access strategy comprising licensing, equity investment, and acquisition deals and conducted technical and commercial due diligence of potential targets. • Led commercial assessment of Evalve, Inc., which culminated in upfront $320M acquisition and solidified Abbott Vascular’s presence in then-emerging Structural Heart space. From 2008 to 2011 (3 years) San Francisco Bay AreaR&D Program Manager @ POSITION PROFILE: Reporting to the VP, R&D and responsible for leading team of 6 Marketing and Therapy Leads with indirect oversight of technical and cross-functional teams to deliver 3 emerging therapy businesses in heart attack prevention, heart failure, and kidney failure. Programs were positioned to drive aggressive growth for ~$2.5B Division. ACHIEVEMENTS: NEW BUSINESS VENTURES EXECUTION • To insure against disruption, Abbott Vascular launched an internal incubator of innovative, integrated therapies and emerging businesses, projected to double the business in the long-range plan, in heart attack prevention, heart failure, and kidney failure. • Directed integrated therapy teams to develop and execute comprehensive global strategic plans, including technology development, market access, and market development strategies, for emerging businesses. • Acted as primary interface to executive steering committee and strategic advisory boards comprising the field’s highest profile KOLs, a responsibility typically reserved for director-level or higher. Secured continued funding. • Emerging Businesses & Integrated Therapy Strategies: o Heart Attack Prevention: High profile initiative to identify patients at-risk for heart attacks, develop market access strategies to channel them to the clinic, and execute a portfolio of products to reduce cardiac events. o Heart Failure: Stem cell therapy delivery to restore cardiac function in patients with progressive heart failure following heart attack. o Kidney Failure: Site specific therapy to slow progression of renal dysfunction in patients with diabetic nephropathy. • These efforts promoted Abbott Vascular’s image as a leading innovator and disruptor in interventional therapies. From 2007 to 2008 (1 year) Emerging Therapy Lead, Heart Attack Prevention @ POSITION PROFILE: Responsible for leading an integrated therapy team, comprised of technical, marketing, and cross-functional members, to deliver technology development, market access, and market development strategies for the Heart Attack Prevention emerging business. ACHIEVEMENTS: NEW BUSINESS VENTURES EXECUTION • Guided execution and analysis of PROSPECT, world’s first prospective natural history study designed to correlate angiography, IVUS, and virtual histology imaging of entire coronary tree; biomarkers; and patient demographics to cardiac events. • Steered development of a coronary scaffold to stabilize vulnerable lesions and a nanoparticle drug delivery technology to reduce coronary plaque burden through controlled release of reverse lipid transport and anti-inflammatory therapeutic agents. From 2005 to 2007 (2 years) San Francisco Bay AreaSenior Engineer/Principal Engineer @ ACHIEVEMENTS: RESEARCH & DEVELOPMENT EXCELLENCE / >50% SHARE $4B MARKET • Assisted in development of XIENCE V® drug-eluting stent coating, optimizing polymer-drug formulation to attain desired mechanical integrity and controlled drug release profile to ensure clinical safety and efficacy. • Collaborated with world-renowned pathologist to develop an animal model to assess healing post-stenting and design key study ultimately used to promote superior healing of XIENCE V® over competitive drug-eluting stents. • One of 15 R&D and marketing personnel chosen by senior management to launch XIENCE V® in friendly accounts during first 2 months of U.S. commercial release, allowing sales reps to focus on key competitive accounts. • These efforts enabled the commercial team to capture >50% market share within 3 months of launch. From 2002 to 2005 (3 years) San Francisco Bay Area

Master of Business Administration (MBA), Finance, 3.9 / 4.0 @ University of Pennsylvania - The Wharton School From 2009 to 2011 Doctor of Philosophy (PhD), Chemical Engineering, 4.0 / 4.0 @ University of Illinois at Urbana-Champaign From 1997 to 2002 Bachelor of Science (BS), Chemical Engineering, 3.9 / 4.0 @ University of Michigan From 1993 to 1997 Jessica DesNoyer is skilled in: FDA, R&D, Biomedical Engineering, Medical Devices, Cross-functional Team Leadership, Commercialization, Strategy, Program Management, Product Development, Biotechnology, Lifesciences, Regulatory Affairs, Pharmaceutical Industry, Leadership, Validation